# Difficulty With Binary Voting Among FDA Oncology Advisory Committee Members

## TL;DR

This study explores how often FDA advisory committee members report difficulty in voting to approve cancer drugs.

## Contribution

The study provides new insights into the challenges faced by FDA advisory committee members during drug approval voting.

## Key findings

- Members frequently report difficulty in binary voting decisions for drug approvals.
- The qualitative analysis reveals factors influencing voting challenges in oncology drug approvals.
- The study highlights the subjective nature of drug approval decisions in advisory committees.

## Abstract

This qualitative study investigates the frequency of reports of difficulty in voting for drug approval by members of the Food and Drug Administration Oncologic Drugs Advisory Committee.